Clinical Trials

Ascendis’ TransCon PTH shows promise in phase 2 hypoparathyroidism trial

Ascendis Pharma said that its prodrug candidate TransCon PTH has met key objectives in the phase 2 PaTH Forward trial in adult subjects with hypoparathyroidism.

5000i – Faster Scale-up of Fermentation Processes

The Kluyver Center for Genomics of Industrial Fermentation in Delft, Holland, is a consortium of several different Universities and Research Centres.

Sinovac Biotech to move ahead with COVID-19 vaccine trial in China

Sinovac Biotech has secured approval in China to move ahead with a human clinical trial on an inactivated vaccine candidate against the SARS-CoV-2 virus (novel coronavirus or COVID-19).

Intensity Therapeutics signs clinical collaboration agreement with Bristol Myers Squibb for advanced solid tumors

Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company.

Hope Biosciences gets FDA nod for phase 2 COVID-19 stem cell therapy trial

Hope Biosciences has been given clearance from the US Food and Drug Administration (FDA) to move ahead with a phase 2 trial to evaluate its investigational stem cell therapy in providing immune support against COVID-19.

Ridgeback Biotherapeutics announces MHRA clearance to begin human testing of EIDD-2801 in UK for COVID-19

Ridgeback Biotherapeutics announced clearance by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for an orally available antiviral compound, EIDD-2801, to begin human testing.  This action by the MHRA allowed Ridgeback to commence Phase 1 in the UK. 

Lilly launches clinical testing of baricitinib and LY3127804 in COVID-19

Eli Lilly and Company (Lilly) has started clinical testing of its oral JAK1/JAK2 inhibitor OLUMIANT (baricitinib) and investigational candidate LY3127804 in separate COVID-19 trials.

Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis

Arrowhead Pharmaceuticals has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to progressive deterioration in lung function due to poor clearance of mucus and associated recurrent infections.

OncoImmune receives FDA approval for COVID-19 clinical trial

OncoImmune has received a study-may-proceed letter from the FDA for its Phase III clinical trial testing the safety and efficacy of CD24Fc for the treatment of hospitalized COVID-19 patients (SAC-COVID).